Work

Rituximab Provides Steroid-Sparing Therapy in New-Onset Chronic Graft-Versus-Host Disease

Year: 2013

Type: article

Abstract: Chronic graft-versus-host disease (cGVHD) remains a complication of allogeneic HCT and treatment remains prednisone dependent with starting dose of 1mg/kg/day. Rituximab shows efficacy in steroid-refractory cGVHD supporting B-cell pathogenesis. We hypothesized that anti-B cell therapy delivered at cGVHD development is effective and steroid-sparing. 35 patients (pts) with new-onset cGVHD, requiring systemic steroid treatment at 1mg/kg/day, received Rituximab 375-mg/m2 weekly x4 within first month of diagnosis.

Source: Transplantation and Cellular Therapy

DOI: 10.1016/j.bbmt.2012.11.081

Authors: Bita Sahaf, Sally Arai, Joanne Otani, Kelsi Schoenrock, Aaron Logan, David B. Miklos

Institutions: Stanford Medicine, Stanford University

Language: English

Topic: Hematopoietic Stem Cell Transplantation

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: hybrid

Estimated APC paid: $3,650